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Aims To assess the prognostic value of myocardial pre-contrast T1 and extracellular volume (ECV) in systemic amyloid light-
chain (AL) amyloidosis using cardiovascular magnetic resonance (CMR) T1 mapping.
Methods
and results
One hundred patients underwent CMR and T1 mapping pre- and post-contrast. Myocardial ECV was calculated at con-
trast equilibrium (ECVi) and 15 min post-bolus (ECVb). Fifty-four healthy volunteers served as controls. Patients were
followed up for a median duration of 23 months and survival analyses were performed. Mean ECVi was raised in
amyloid (0.44+0.12) as was ECVb (mean 0.44+0.12) compared with healthy volunteers (0.25+ 0.02), P, 0.001.
Native pre-contrast T1 was raised in amyloid (mean 1080+87 ms vs. 954+34 ms, P, 0.001). All three correlated
with pre-test probability of cardiac involvement, cardiac biomarkers, and systolic and diastolic dysfunction. During
follow-up, 25 deaths occurred. An ECVi of.0.45 carried a hazard ratio (HR) for death of 3.84 [95% confidence interval
(CI): 1.53–9.61], P ¼ 0.004 and pre-contrast T1 of .1044 ms ¼ HR 5.39 (95% CI: 1.24–23.4), P ¼ 0.02. Extracellular
volumeafter primed infusion andECVb performed similarly. Isolated post-contrast T1was non-predictive. InCox regres-
sion models, ECVi was independently predictive of mortality (HR ¼ 4.41, 95% CI: 1.35–14.4) after adjusting for E:E′,
ejection fraction, diastolic dysfunction grade, and NT-proBNP.
Conclusion Myocardial ECV (bolus or infusion technique) and pre-contrast T1 are biomarkers for cardiac AL amyloid and they
predict mortality in systemic amyloidosis.
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Introduction
Systemic amyloid light-chain (AL) amyloidosis is amultiorgan, infiltra-
tive disorder caused by an underlying plasma cell dyscrasia and is
characterized by tissue and organ amyloid depositionwith interstitial
expansion. Cardiac involvement is present in 50% of patients at
presentation and is the principal driver of prognosis. Treatment
comprises chemotherapy or autologous stem cell transplantation
to suppress clonal light-chain production, which may retard disease
progression or facilitate regression.1
Current predictors of survival rely on measuring surrogate rather
than direct markers of interstitial expansion. Concentration of the
serum biomarkers NT-proBNP and Troponin T form the basis of
the Mayo Staging classification2 but are influenced by renal impair-
ment which is present in a quarter of patients at presentation. ECG
criteria, low limb lead voltages,3 or fragmented QRS complexes4
are also predictive, but are confounded by pericardial effusions
and conduction abnormalities. Echocardiographic parameters also
predict outcome,5–7 but coexisting causes of left ventricular hyper-
trophy or diastolic impairment may affect interpretation.
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Cardiovascularmagnetic resonance(CMR)using the late-gadolinium
enhancement (LGE) technique adds value in the diagnosis of cardiac
involvement in AL amyloidosis. Altered gadolinium kinetics also
shows some correlation with survival.8 Recently we have shown that
pre-contrast, native myocardial T1 mapping correlates with cardiac
disease burden and detects early disease.9 T1 mapping pre- and post-
contrast can be used to derive the partition coefficient and, with the
haematocrit, the myocardial extracellular volume (ECV)10–12 which
is a direct measurement of myocardial interstitium and therefore
likely a surrogate marker of amyloid burden.13,14 The ECV can also
assess amyloid burden in other organs.15 Furthermore, in other
cardiac diseases, myocardial ECV predicts outcome.16
Technically, measurement of the ECV requires equilibration of
contrast concentrations between blood and myocardium, which
can be achieved precisely using a somewhat cumbersome primed
contrast infusion,10 or sufficiently through delayed study following
administration of a bolus of gadolinium. Both techniques measure
ECV the same where the ECVs are typically 0.4 or less, but one
paper has shown a bias towards over-estimation of the true ECV in
high ECV conditions (including n ¼ 20 amyloid patients).17
We hypothesized firstly that the myocardial ECV and pre-contrast
T1 would correlate with disease burden in cardiac AL amyloidosis as
assessed by current measures. Additionally, we tested the ability of
bothbiomarkersaspredictorsofsurvival inALamyloidosisbycompar-
ing the predictive power of: ECV after primed infusion (ECVi);
pre-contrast T1; bolus-only ECV (ECVb); and post-contrast T1.
Methods
The researchwas approvedbyTheUCL/UCLH JointCommitteeson the
Ethics of Human Research Committee and all participants provided
informed,written consent prior to enrolment.Onehundredconsecutive
patients with systemic AL amyloidosis whowere assessed between 2010
and 2012 at the National Amyloidosis Centre (Royal Free Hospital,
London, UK) and in whom there were no contraindications to CMR
(presence of non-MR compatible devices) or contrast administration
(GFR , 30 mLs/min) or potential confounders to T1 measurement
(known atrial fibrillation at first visit) were recruited. These 100 patients
include all 60 patients studied previously in the baseline study.13Approxi-
mately 25% of patients with systemic AL amyloidosis seen at the centre
during this period had an eGFRof,30 mL/min/1.73 m2 andwere there-
fore excluded. Six patients who were found to have atrial fibrillation/
flutter once in the scanner after they had consented were not excluded.
All patients had histological proof of systemic AL amyloidosis except 2
(2%), who died before biopsy could be undertaken, but in whommono-
clonal gammopathies were present and the organ distribution of amyloid
on SAP scintigraphy was characteristic of AL type. Histology was per-
formed with Congo red followed by immunohistochemical staining;
tissues examined were: kidney (26%), endomyocardium (7%), bone
marrow (13%), upper gastrointestinal tract (7%), liver (3%), fat (15%),
spleen (1%), lung (1%), rectum (9%), soft tissues (12%, included skin,
tongue, buccal mucosa, labia), lymph node (3%), and peritoneum (1%).
All patients underwent 12 lead ECG, assays of the cardiac biomarkers
NT-proBNP and Troponin T, and echocardiography at baseline. Mean
ECGQRSvoltage in limb andpraecordial leadswere calculated.18 Echocar-
diographic assessment of diastolic function was performed using the E:E′
ratio.Where transmitral E-wavedeceleration timeand isovolumetric relax-
ation timewere available, a diastolic dysfunction grade of 0–3was assigned
according to established British Society of Echocardiography (BSE) criteria.
All additionally underwent conventional CMR on a 1.5 T magnet
(Avanto, Siemens). T1 mapping was performed using the Shortened
Modified Look Lockers Inversion (ShMOLLI) recovery sequence19 pre-
and post-contrast (0.1 mmol/kg bolus and 0.0011 mmol/kg/min infusion
ofDotaremTM) as part of the EquilibriumCMR (EQ-CMR) technique, the
post-contrast T1 map being performed at 15 min and after equilibration
(mean time from bolus 45 min), as previously described.10
Analysis
StandardCMRparameters of structure (left ventricle (LV)mass, left atrial
area with/without indexing for body surface area, maximal septal thick-
ness) and systolic function [ejection fraction, mitral annular plane systolic
excursion (MAPSE), Tricuspid annular plane systolic excursion (TAPSE)]
were assessed. A region of interest (ROI) was drawn in the basal septum
in a four-chamber view in all patients and in the left atrium for blood T1
measurement as papillary muscle hypertrophy made drawing an ROI in
the LV cavity challenging (see Figure 1); ROIs were mid-myocardial (at
Figure1 Showing (A) pre-contrast and (B) post-contrast, four-chamber ShMOLLI imagewith regions of interest drawn in the left atrium for blood
T1measurement and in the basal septumof left ventricle, excluding at least the first two pixels of endocardiumon either side of the septum in order
to avoid through planing of blood pool.
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least twopixels away from the apparent blood:myocardial boundary) and
were drawn without reference to the LGE images (see Figure 1).13 We
quantified interstitial expansion with the ECV as described previously:
ECV ¼ l(12 haematocrit), where l ¼ [DR1myocardium]/[DR1blood pool]
pre- and post-Gd (where R1 ¼ 1/T1).
Some ECV data (n ¼ 19 of the 100) pre-dated availability of ShMOLLI
T1 mapping and had utilized multibreath-hold T1 measurement.10 We
have demonstrated equivalence of ECV values derived from this tech-
nique with ShMOLLI ECV and so these data were not excluded from
the analyses.20
That said, these patients did not have an ECVb value or the subsidiary
component of the ECVequation, pre-contrast T1;multibreath-holdmeas-
urement has been shown to be inferior to T1 mapping, so accordingly,
these were excluded from the sub-analysis comparing techniques—this
particular analysis therefore consists of 81 rather than 100 patients.
Extracellular volume and myocardial T1 results were compared with
54 healthy volunteers who underwent pre-contrast T1 mapping and
ECV measurement (bolus and infusion). The number of patients dead
and alive was assessed after a median duration of 23 (interquartile
range: 6–25) months. Some analysis involved sub-grouping patients
into pre-test probability of cardiac involvement. This was done as previ-
ously described and as stated below.
Definite cardiac involvement—any of:
† Left ventricle (LV) wall thickness of ≥12 mm by echocardiography in
the absence of any other known cause
† Right ventricle (RV) freewall thickening co-existingwith LV thickening
by echocardiography in the absence of systemic or pulmonary
hypertension
Possible cardiac involvement—any of:
† LV wall thickening by echocardiography in the presence of
hypertension
† RV thickening by echocardiography in the presence of pulmonary
hypertension
† Normal wall thickness by echocardiographywith diastolic dysfunction
and raised serum biomarkers2
No suspected involvement:
† Normal wall thickness by echocardiography with normal serum
biomarkers
Statistical analysis
Study data were collected and managed using REDCap (Research Elec-
tronic Data Capture) electronic data capture tools hosted at University
College London.21 Analysis was performed using SPSS (IBM Corp.
Released 2012. IBM SPSS Statistics for Windows, Version 21.0.
Armonk,NY: IBMCorp), R programming language for statistical comput-
ing (version 3.0.1, The R Foundation for Statistical Computing) and in
Stata (StataCorp. 2011. Stata Statistical Software: Release 12. College
Station, TX: StataCorp LP). All continuous variables were normally dis-
tributed except NT-proBNP and Troponin T which were log (ln) trans-
formed (base e) to achieve normality for further analysis. Linear
regression models measured the association between quantitative ECV
and other variables; variance inflation factors ,2 excluded collinearity.
Pearson’s correlation coefficients are presented in terms of R values.
Means are presented+SD. Thex2 testwas used to compare categorical
variables between patients and controls whilst the unpaired t-test was
used tocomparecontinuous variablesbetween thepatients andcontrols.
A one-way ANOVA with Bonferroni correction was used to test ECV
with pre-test clinical probability of cardiac involvement.13
To test the prognostic value of ECV and pre-contrast T1, survival was
evaluated using Cox proportional hazards regression analysis, providing
estimated hazard ratios (HRs) with 95% confidence intervals (CIs) and
Kaplan–Meier curves. Conventional ROC analysis could not be per-
formed because the follow-up period was not the same for each
patient. Therefore, time-dependent ROC curves22 were used to assess
the capacity of ECVi compared with ECVb and pre-contrast myocardial
T1 for discriminating between surviving and dying patients with AL amyl-
oidosis. For fixed times (t ¼ 12 months, t ¼ 24 months) and specificity
level, we have compared the sensitivity of ECVi, ECVb, and pre-contrast
myocardial T1 measurements for detecting patients whowill die by time
t. For theROCcurves constructed using the nearest neighbourestimator
(NNE)weused a narrow span ofl (0.25 × nobs20.20) to yield onlymod-
erate smoothing. To permit comparison of ROCs by theNNE estimator,
a set of simple KM estimator ROC curves for this data at t ¼ 24 months
are also provided (see Supplementary material online, Figure S1).
Optimal myocardial T1 and ECV values were explored byCox regres-
sion, using the median and the 1st or 2nd tertiles as cut-off values. The
twogroups resulting fromeachcut-offwere comparedusing theHarrell’s
C statistic (a measure of discrimination between groups) to determine
the bettermodel and thus biomarker for predicting survival. All variables
were first exploredwith univariate Cox regression.Multivariablemodels
evaluated the independent predictive value of ECV above other clinically
and statistically significant covariates.
Results
Table 1 summarizes baseline characteristics for patients and healthy
volunteers. Within the patient cohort, 14 (14%) patients were on
treatment for hypertension; 10 (10%) had confirmed coronary
artery disease by angiography, 1 (1%) had had a stroke, and 2 (2%)
had diabetes. Fifty patients were treated with chemotherapy for
the first time which comprised triple therapy with either cyclophos-
phamide, thalidomide, and dexamethasone or cyclophosphamide,
bortezomib and dexamethasone (CVD), depending on local guide-
lines of regional NHS Trusts within the UK. Seventeen patients
were treated for a 2nd or 3rd time having relapsed—treatment
was either with CVD or a lenalidomide-containing regimen in these
instances. Nine patients had not received any chemotherapy as
there was no clinical indication (e.g. renal amyloid with established
renal failure, isolated neuropathic presentations) and 24 patients
were under a stable follow-up with no indication for further chemo-
therapy at the time of scan.
Twenty-one patients had a pre-test probability of no cardiac in-
volvement, 26 had possible cardiac involvement, and 53 had definite
cardiac involvement.
All ECV values are the ECVi from infusion measurement unless
otherwise stated. Healthy controls were younger on average, but
our work and others suggests any ECV changes with age are small
compared with amyloid changes.23,24 There were proportionately
more females in the control vs. the patient group. This slightly
increases the control group ECV and pre-contrast T1 compared
with that of a gender-matched group (male vs. female: ECV 0.24 vs.
0.27, P, 0.001; T1 940 vs. 966 ms, P ¼ 0.006).
As in previous work, mean cardiac ECV was greater in patients
compared with healthy volunteers with a wider range (0.44+0.12
vs. 0.25+ 0.02, P, 0.001) and correlated with pre-test probability
of cardiac involvement by conventional parameters (P, 0.001)13
(see Supplementary material online, Figure S2). Mean pre-contrast
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myocardial T1 values were raised in patients compared with healthy
volunteers (1080+87 ms vs. 954+34 ms, P, 0.001) and also cor-
relatedwith pre-test probability of cardiac involvement (P, 0.001).9
Table 2 provides the Pearson correlation coefficients of ECV,
pre-contrast and post-contrast myocardial T1 to other cardiac
parameters,manyofwhich typically change in cardiac amyloid. Extra-
cellular volume correlated significantlywith 17of 19; pre-contrast T1
with 12, and post-contrast T1 with 10.
With regards LGE, 25 patients had noLGE, 50 had global subendo-
cardial enhancement, and 10 had extensive enhancement. Eight
had patchy enhancement and seven had evidence of only altered
gadolinium kinetics, i.e. reversed nulling of myocardium and blood
after gadolinium administration. Extracellular volume correlated
significantly with increasing degrees of LGE (P, 0.001) as shown
in Figure 2.
At follow-up (median 23 months), 25 of 100 patients had died.
For each potential predictor, median and tertile cut-points were
assessed for predictive power and the best result presented (see
Table 3).
For ECVi, a median ECV of 0.45 was the best predictor of survival:
HR 3.84 (1.53–9.61), P ¼ 0.004 (Figure 3). The survival curve indi-
cates that there is an 40% chance of death at 23months in patients
with an ECV ≥ 0.45 comparedwith 15% for patients with an ECV,
0.45. For pre-contrast myocardial T1, the 1st tertile (cut-point
1044 ms) was the best predictor: HR 5.39 (1.24–23.4), P ¼ 0.02
(Figure 4A). ECVb with median of 0.44 also predicted survival with
an HR of 5.09 (1.09–23.7), P ¼ 0.04 (Figure 4B). Post-contrast T1
did not predict survival (HR ¼ 0.5, P ¼ 0.11).
When the three predictive models ECVi, ECVb, and pre-contrast
T1 were compared to determine the stronger discriminator using
theHarrell’s C statistic (the higher the number, the stronger discrim-
inator), all three performed similarly (see Table 3). The time-
dependent ROC analysis revealed that overall (considering both
earlier [t ¼ 12] and later [t ¼ 24] follow-up times), the three ROC
curves for ECVi, ECVb, and pre-contrast T1 show quite similar dis-
crimination for cumulative mortality (see Figure 5).
The value ECVi . 0.45 remained significantly associated with
mortality (HR ¼ 4.41, 95% CI 1.35–14.4; P ¼ 0.01) in multivariable
Coxmodels that included measures of systolic and diastolic function
and serum biomarkers: E:E′, diastolic dysfunction grade (≥2),
ejection fraction, and LnNT-proBNP (troponin was not available in
all patients). E:E′ and NT-ProBNP also remained independently
predictive.
Discussion
Extracellular volume is the first, non-invasive quantifier of the cardiac
interstitium, while pre-contrast T1 is a composite measure of inter-
stitium and myocardial cells. This study demonstrated that ECV and
native myocardial T1 as measured by the newer T1 mapping techni-
ques, both correlate with current markers of disease severity in
cardiac AL amyloidosis, supporting previous work.11–13 We have
also demonstrated that both these biomarkers have ‘real-world’
clinical significance in that both are predictors of mortality in AL
amyloidosis.
Amyloidosis is the exemplary interstitial disease of the myocar-
dium. Cardiac involvement portends a poor prognosis which has
driven the need for better methods of detecting early cardiac
disease. We previously described both pre-contrast T1 mapping
and ECVmeasurement as potential, non-invasive techniques for dir-
ectly measuring the cardiac AL disease burden in amyloid.13 Here,
these early results are strengthened by increased numbers and, add-
itionally, prognostic significance of the biomarkers is demonstrated,
even with therapy. The half of AL amyloid patients with an ECV.
0.45 had a three- to four-fold increased likelihood of death—
roughly a 35–40% chance of death at 23 months compared with
lower ECV patients despite therapy, lending support to ECV as a
key amyloid biomarker.
Recent work published in this journal in non-amyloid patients,
where ECV likely measures diffuse fibrosis, has also showed predict-
ivepower—in1176consecutiveCMRreferral patientsover amedian
of 1.3 years follow-up, 24deathsoccurredwithECVcarrying ahazard
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 1 Baseline characteristics of the 100 AL amyloidosis patients and 54 healthy controls
Characteristic Patients Healthy controls P value
Male/female 67/33 25/29 0.01
Mean age+ SD (years) 62+10 46+15 0.001
Mean creatinine+ SD (mmol/L) 89+32 74+13 0.001
Mean NYHA (I/II/III/IV) 29/56/15/0 –
Mean EF+ SD (%) 66+11 67+6 0.42
Diastolic dysfunction grade (0/1/2/3)a 15/36/25/22 –
Mean indexed end-diastolic LV volume+ SD (mLs) 60+14 73+12 0.001
Mean indexed end-systolic LV volume+ SD (mLs) 19+10 25+7 0.001
Mean indexed LV mass+ SD(g/m2) 96+34 65+15 0.001
Mean indexed LA area 13+3 9+1.5 0.001
Median NT-proBNP in pmol/L (IQ range) 146 (38–359) –
Median troponin T in ng/L (IQ range) 0.03 (0.01–0.06) –
AF/atrial flutter (%) 6 (6) 0
aTwo patients did not have all three diastolic markers measured due to poor windows and therefore could not be graded as per BSE guidelines.
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ratio of 1.52 (1.21–1.89) for admissions with heart failure and all-
causemortality.16 Here, we have demonstrated that ECV adds incre-
mental value over and above existing clinical markers when risk-
stratifying patients. Unfortunately, it was not possible to include
NYHA class in the multivariable model because this information
was not available in all patients due to other factors limiting exertion
such as peripheral and autonomic neuropathy due to systemic amyl-
oidosis. Additionally, the limited number of deaths limits very exten-
sive multivariable analysis so this may not represent the optimal
multivariable model.
Weused an arbitrary categorization for thepresenceorotherwise
of cardiac amyloid. The Mayo staging system is the most recognized
predictor of survival in systemic AL amyloidosis.2 In new presenta-
tions, median survival was reduced from 26 to 10 months when
either NT-proBNP or Troponin T was raised and reduced further
still to only 3 months if both biomarkers were raised, although the
authors are in theprocessof further refining thismodelwith inclusion
of values for serum-free light-chain concentration.25 Our survival
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Table 2 Extracellular volume, pre-, and post-contrast T1 correlations (Pearson’s R correlations) with cardiac structure
and function, biomarkers and ECG changes in light-chain amyloid patients
ECV Myocardial T1
Pre-contrast Post-contrast
R P-value R P-value R P-value
LV structure by CMR
LV mass 0.49 ,0.001 0.44 0.001 0.44 0.001
Indexed LV mass 0.50 0.001 0.44 0.001 0.41 0.001
Septal thickness 0.61 0.001 0.54 0.001 0.35 0.001
LA area 0.31 0.002 0.13 0.25 0.22 0.054
Indexed LA area 0.29 0.003 0.11 0.35 0.11 0.35
LV systolic function by CMR
Ejection fraction 0.46 0.001 0.31 0.004 0.22 0.045
MAPSE
a
0.59 0.001 0.53 0.001 0.25 0.023
LV end-diastolic volume 0.05 0.64 0.12 0.28 0.15 0.18
LV end-systolic volume 0.31 0.002 0.15 0.19 0.06 0.58
Indexed LV end-diastolic volume 0.10 0.32 0.17 0.13 0.27 0.01
Indexed LV end-systolic volume 0.31 0.002 0.13 0.23 0.04 0.73
LV diastolic function by echo
E:E′ 0.35 0.001 0.25 0.03 0.34 0.002
IVRT 0.37 0.002 0.32 0.02 0.19 0.17
E-deceleration time 0.24 0.02 0.37 0.001 0.07 0.51
RV systolic function by CMR
TAPSE$
b
0.53 0.001 0.50 0.001 0.42 0.001
Biomarkers
Serum NT-pro-BNP (LnNT-proBNP) 0.65 0.001 0.58 0.001 0.35 0.001
Troponin T (lnTropT) 0.43 0.02 0.28 0.07 0.24 0.12
ECG
ECG limb lead mean voltage 0.43 0.001 0.37 0.001 0.10 0.40
ECG chest lead mean voltage 0.22 0.03 0.13 0.27 0.24 0.03
aMitral annular plane systolic excursion.
$bTricuspid annular plane systolic excursion.
Figure 2 Dot plot showing correlation between extracellular
volume and late-gadolinium enhancement.
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data in the 49 patients scanned at presentation is currently under-
powered to determine any incremental benefit of ECV in this specific
patient group; this remains work in progress.
Extracellular volume is predictive, regardless of treatment status
and indeed irrespective ofwhether patients are presenting at diagno-
sis or years into the disease process. Some patients in the cohort had
modest ECV increases (ECV 0.30–0.40) without any other evidence
of cardiac involvement (no LGE, no wall thickness increase, and no
biomarker elevation), reinforcing our original findings that even
patients classified as having no cardiac amyloid do in fact have
raised ECVs, suggestive of low-grade cardiac disease. A plausible
role for aggressive therapy in such patients to prevent progression
to overt cardiac disease can be entertained.13
Although T1 mapping is now more mature with sequences avail-
able on all platforms, it is difficult to compare ECV and T1 to LGE
because, as previously stated, the absence of LGE likely does not
equate to the absolute absence of cardiac amyloid and PSIR
imaging which can be helpful with LGE imaging in amyloid, is not
available on all platforms. We have previously demonstrated that
when ROIs are drawn in LGE-positive and LGE-negative areas in
the same patient, the ECV, whilst lower in LGE-negative areas, is
still not normal.13
The simpler pre-contrast myocardial T1 technique does not
require a contrast agent and shows promise,9 particularly as 20–
30% of patients with systemic AL amyloidosis have an eGFR of
,30 mL/min at presentation and in these patients, the Mayo
staging system is in part confounded by elevation of serum biomar-
kers due to renal dysfunction. Here, pre-contrast myocardial T1 by
ShMOLLI is an alternative to ECV. It is an equally strong predictor
but as mentioned earlier, it represents a composite signal from
cells and interstitium, not just the interstitium alone like ECV. Some
work may be needed to derive normal pre-contrast T1 values in
patients with renal impairment due to non-amyloid-related patholo-
gies. An additional issue is that pre-contrast T1 presents greater
standardization challenges.
From a practical perspective, the bolus only approach to ECV
(ECVb) was as good as ECVi. Our previous work showed that, in
most disease states, ECVb carried excellent agreement with ECVi
when the tissue ECV was ,0.4, but generated higher results in
high ECV scenarios—such as areas of scar and amyloid.17 Nonethe-
less, this study suggests that theECVbpasses akeyclinical utility testof
being prognostic. Post-contrast T1, however, was not useful either at
baseline or to predict outcome.
Limitations of the study are that patients were followed up for dif-
ferent time periods and are at different disease and treatment stages,
with treatment here reflecting current UK practice. The causes of
death are not knownas patients die locally and theNationalAmyloid-
osis centre receives only notification of death rather than cause of
death; however, it is widely accepted that most deaths are cardiac.
Studies looking to correlate ECV change with haematological and
clinical response as well as histology in AL amyloidosis have yet to
be performed. Whole heart ECV calculations were not possible in
this study because of through-planning of blood pool (due to
cardiac motion in the superior–inferior plane) in areas of thinner
myocardium towards the apex but as technology advances with
motion correction T1mapping sequences, this will become possible.
As stated earlier, the number of events limits extensive analysis. That
said, these are nevertheless hard endpoints andmultivariable analysis
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 3 Median and tertiles for extracellular volume after primed infusion and pre-contrast T1 with associated Hazard
Ratios by Cox regression and Harrell’s C statistic
Tertile Cut-point HR (95% CI) P-value Harrell’s C statistic
ECVi Tertile 1 0.40 4.67 (1.39–15.5) 0.013 0.63
Median 0.45 3.83 (1.53–9.61) 0.004 0.66
Tertile 2 0.49 3.61 (1.56–8.38) 0.003 0.65
Pre-contrast myocardial T1 Tertile 1 1044 ms 5.39 (1.24–23.4) 0.02 0.64
Median 1080 ms 3.01 (1.08–8.44) 0.035 0.62
Tertile 2 1116 ms 3.22 (1.30–8.04) 0.01 0.63
ECVb Median 0.44 5.09 (1.09–23.7) 0.03 0.68
Post-contrast T1 Median 565 ms 0.45 (0.17–1.20) 0.11 0.41
Cox regression and Harrell’s C statistic also shown for median ECVb and post-contrast T1.
Figure 3 Kaplan–Meier survival curves for extracellular volume
after primed infusion.
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Figure 4 Kaplan–Meier survival curves for (A) pre-contrast myocardial T1 and (B) extracellular volume at bolus (NB: although the median of
0.44 was used, the groups are not equal because more than 1 patient had an extracellular volume of 0.44).
Figure 5 Time-dependent receiver operating characteristic curves for extracellular volume after primed infusion, extracellular volume at bolus
and pre-contrast myocardial T1 and survival using nearest neighbour estimator method at time: (top 3) 12 months and (bottom 3) 24 months.
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can still be performed in these situations.26 Whether ECV and pre-
contrast T1—which are not entirely concordant—provide different
pathological insights is at this stage unknown.
Conclusions
The myocardialextracellular volume, ECV, is a recently developed,
non-invasive quantifier of cardiac amyloidosis. We confirm earlier
results that ECV increases with established disease and detects
early cardiac involvement. Extracellular volume after primed infusion
is a promising clinical biomarkerwhich passes a key test as a predictor
of mortality. The pre-contrast T1 mapping method and the faster
bolus-only ECV measurement techniques are equally prognostic,
providing options for patients in renal failure or, in combination
add robustness and diagnostic confidence.
Supplementary material
Supplementary material is available at European Heart Journal online.
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